NCT06966180 (PROB-AIP) is a NA clinical trial of Alcohol Intervention Program (AIP) in Alcohol Use Disorder, sponsored by Mine Pazarcikci.

Who is sponsoring NCT06966180?

NCT06966180 is sponsored by Mine Pazarcikci.

What drugs are being tested in NCT06966180?

Interventions in NCT06966180: Alcohol Intervention Program (AIP).

What condition does NCT06966180 study?

NCT06966180 studies Alcohol Use Disorder, Problem Drinking, Psychosocial Intervention.

Is NCT06966180 still recruiting?

NCT06966180 is currently completed. Last updated 14 May 2025.

Last reviewed 2025-05-14 · How we verify

NCT06966180: PROB-AIP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development and Effectiveness of an Alcohol Intervention Program for Adults Under Probation

Completed NA Last updated 14 May 2025

What this trial tests

NA trial testing Alcohol Intervention Program (AIP) in Alcohol Use Disorder in 115 participants. Completed in 11 May 2024.

Timeline

1 June 2023

Primary endpoint
1 November 2023

11 May 2024

Quick facts

Lead sponsor	Mine Pazarcikci
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	115
Start date	1 June 2023
Primary completion	1 November 2023
Estimated completion	11 May 2024
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Alcohol Intervention Program (AIP)

Conditions studied

Alcohol Use Disorder — all drugs for Alcohol Use Disorder →
Problem Drinking — all drugs for Problem Drinking →
Psychosocial Intervention — all drugs for Psychosocial Intervention →

Sponsor

Mine Pazarcikci

Who can join

18 and older, any sex, with Alcohol Use Disorder or Problem Drinking. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to develop and evaluate the effectiveness of an alcohol-specific intervention program for adult individuals on probation who have problems related to alcohol use. The study was designed as a single-blind randomized controlled trial and was conducted at the Izmir Probation Directorate with a total of 115 participants, 58 in the intervention group and 57 in the control group. When comparing the results between the intervention and control groups, the Alcohol Intervention Program-which consisted of six structured sessions-was found to be effective in reducing participants' alcohol consumption and related problems, while also increasing their motivation for change. This research is significant as it represents the first intervention program developed specifically for alcohol use within the probation system. While existing interventions in both Turkey and abroad often focus on individuals who use illicit substances, alcohol-related problems are frequently overlooked. The results of this study aim to meet that systemic need. The Alcohol Intervention Program developed here can be integrated into routine practices within the scope of educational improvement programs in the probation system.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Alcohol Use Disorder

Currently open trials in the same condition.

NCT06860607 — Environment and Alcohol: A Pilot Study · Phase 1 · recruiting
NCT07325266 — Human Laboratory Study of Apremilast for Alcohol Use Disorder · Phase 2 · recruiting
NCT07046819 — Tirzepatide in MetALD · Phase 2 · recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06966180 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mine Pazarcikci
Last refreshed: 14 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06966180.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing